Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
97 hedge funds and large institutions have $166M invested in Enzo Biochem, Inc. in 2018 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 29 increasing their positions, 38 reducing their positions, and 22 closing their positions.
916% more call options, than puts
Call options by funds: $376K | Put options by funds: $37K
13% more capital invested
Capital invested by funds: $146M → $166M (+$19.6M)
9% less funds holding
Funds holding: 107 → 97 (-10)
24% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 38
45% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EGA
Evermore Global Advisors
Summit,
New Jersey
|
+$28.9M |
| 2 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$10.3M |
| 3 |
BlackRock
New York
|
+$1.91M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$956K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$762K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.3M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$1.79M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$1.67M |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$1.24M |
| 5 |
KIA
Kopp Investment Advisors
Bloomington,
Minnesota
|
-$792K |
ENZ Hedge Fund Activity: Q2 2018 in Review
97 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q2 2018, worth a combined $166M — up 13% from $146M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ENZ and 12 opened new positions — a net loss of 10 holders — while 38 trimmed existing stakes and 29 added.
The largest buyer was Evermore Global Advisors, opening a new position worth an estimated $28.9M. The largest seller was Millennium Management, cutting an estimated $2.3M.
- 97 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q2 2018, down from 107 in Q1 2018.
- Funds reported $166M of Enzo Biochem, Inc. stock for Q2 2018, up 13% quarter-over-quarter.
- 12 funds opened new Enzo Biochem, Inc. positions in Q2 2018 and 22 closed out, a net change of -10 holders.
- The largest Enzo Biochem, Inc. buyer in Q2 2018 was Evermore Global Advisors, an estimated $28.9M added.
- The largest Enzo Biochem, Inc. seller in Q2 2018 was Millennium Management, an estimated $2.3M sold.
Based on aggregated 13F filings for Q2 2018.